Shorter (≤ 6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized clinical trials

Catheterization and Cardiovascular Interventions

Volumn 85, Issue 1, 2015, Pages 34-40

  Pandit, Anil ^a   Giri, Smith ^b   Hakim, Fayaz Ahmad ^a   Fortuin, F David ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antiplatelet therapy; Coronary artery disease; Drug eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y12 RECEPTOR;

ARTICLE; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; DATA ANALYSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STENT THROMBOSIS; TREATMENT DURATION; ADVERSE EFFECTS; CEREBROVASCULAR DISORDERS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CORONARY THROMBOSIS; DEVICES; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RISK; TIME; TREATMENT OUTCOME;

ASPIRIN; CEREBROVASCULAR DISORDERS; CHI-SQUARE DISTRIBUTION; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PURINERGIC P2Y12; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923205768     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25520     Document Type: Article

References (18)

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 accf/aha/scai guideline for percutaneous coronary intervention: A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 2011;124:e574-e651.
2. Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ, Observation CICftRoED. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators P, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, Investigators T-T. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
5. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007;369:667-678.
6. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168.
7. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, Investigators C. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.
8. Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, Valgimigli M. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: A prodigy trial substudy (prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia). J Am Coll Cardiol 2014;63:506-512.
9. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The efficacy of xience/promus versus cypher to reduce late loss after stenting (excellent) randomized, multicenter study. Circulation 2012;125:505-513.
10. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y, Investigators R. A new strategy for discontinuation of dual antiplatelet therapy: The reset trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340-1348.
11. Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, Zuffi A, Colombo F, Kubbajeh M, Cavazza C, Cangiano E, Tebaldi M, Minarelli M, Arcozzi C, Scalone A, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in allcomer patients undergoing percutaneous coronary intervention design and rationale for the prolonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia study (prodigy). Am Heart J 2010;160:804-811.
12. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB, 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Jr., Nicolela EL, Jr., Perin MA, Devito FS, Labrunie A, Salvadori D, Jr., Gusmao M, Staico R, Costa JR, Jr., de Castro JP, Abizaid AS, Bhatt DL, Investigators OT. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The optimize randomized trial. JAMA 2013;310:2510-2522.
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009;339:b2700.
14. Feres F, Costa RA, Bhatt DL, Leon MB, Botelho RV, King SB, 3rd, de Paula JE, Mangione JA, Salvadori D, Jr., Gusmao MO, Castello H, Jr., Nicolela E, Jr., Perin MA, Devito FS, Marin-Neto JA, Abizaid A. Optimized duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (optimize) trial: Rationale and design of a large-scale, randomized, multicenter study. Am Heart J 2012;164:810-816.
15. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R, Investigators PRDataGs-iIhs. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (prodigy). Eur Heart J 2013;34:909-919.
16. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: A meta-analysis of randomized trials. Eur Heart J 2012;33:3078-3087.
17. Valgimigli M, Park SJ, Kim HS, Park KW, Park DW, Tricoci P, Ferrante G. Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials. Int J Cardiol 2013;168:2579-2587.
18. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-1382.